Innoviva vs Travere Therapeutics
Travere Therapeutics reported revenue of $491 million in fiscal 2025, 1.2 times Innoviva's $411 million in fiscal 2025. Innoviva's revenue grew 14.7% in its latest year, and Travere Therapeutics' grew 110.5%. Innoviva had an operating margin of 39.8%, against -12.8% at Travere Therapeutics.
Side by side
| Innoviva | Travere Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $411M | $491M |
| Revenue growth | 14.7% | 110.5% |
| Revenue growth a year, last 5 years | 4.1% | 19.9% |
| Gross margin | 74.8% | 97.9% |
| Operating margin | 39.8% | −12.8% |
| Net margin | 65.9% | −5.2% |
| Free cash flow | $196M | — |
| Free cash flow margin | 47.6% | — |
| Return on capital | 17.9% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $4M | $0M |
| Change in diluted share count | 14.2% | 13.1% |
| Last close | $19.03 | $50.65 |
| P/E at the last close | 9.5× | — |
| Insider trades, last 12 months | — | sold $95.9 million |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InnovivaTravere Therapeutics
Operating margin
Percent of revenue
InnovivaTravere Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnovivaTravere Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Innoviva and Travere Therapeutics pages.